Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

"The scale and scope of data to be presented at the ASCO GU meeting underscore the impact our whole-transcriptome-based Decipher tests are having in treating patients with urologic cancers, and how ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States ...

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company ...

How to Protect and Secure Your Data in 10 Ways Your email has been sent Use this comprehensive list of strategies to help you safeguard your company's data from threats and data breaches.

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of $125.00. Justin Zelin has given his Buy rating due to a ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...

Viking Therapeutics (NASDAQ: VKTX) seems to fit the bill, as it announced fantastic data from trials of ... agonists and has a candidate, VK2735, in late-stage clinical trials.